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Abstract
Objectives—To estimate the effectiveness of candidate microbicides BufferGel and 0.5% PRO 
2000 Gel (P) (PRO 2000) for prevention of non-ulcerative sexually transmitted infections (STIs).
Methods—Between 2005 and 2007, 3099 women were enrolled in HIV Prevention Trials 
Network (HPTN) protocol 035, a phase II/IIb evaluation of the safety and effectiveness of 
BufferGel and PRO 2000 for prevention of sexually transmitted infections, including Neisseria 
gonorrhoeae (GC), Chlamydia trachomatis (CT), and Trichomonas vaginalis (TV). Incidences of 
STIs were determined by study arm, and hazard ratios (HRs) of BufferGel and PRO 2000 versus 
placebo gel or no gel control groups were computed using discrete time Andersen-Gill 
proportional hazards model.
Results—The overall incidence rates were 1.6/100 person-years at risk (PYAR) for GC, 3.9/100 
PYAR for CT, and 15.3/100 PYAR for TV. For BufferGel versus placebo gel, HRs were 0.99 
(95% CI 0.49–2.00), 1.00 (95% CI 0.64–1.57), and 0.95 (95% CI 0.71–1.25) for prevention of 
GC, CT, and TV respectively. For PRO 2000, HRs were 1.66 (95% CI 0.90–3.06), 1.16 (95% CI 
0.76–1.79), and 1.18 (95% CI 0.90–1.53) for prevention of GC, CT, and TV respectively.
Conclusions—The incidence of STIs was high during HPTN 035 despite provision of free 
condoms and comprehensive risk-reduction counselling, highlighting the need for effective STI 
prevention programmes in this population. Unfortunately, candidate microbicides BufferGel and 
PRO2000 had no protective effect against gonorrhoea, Chlamydia, or trichomoniasis.
Keywords
Neisseria gonorrhoeae; Chlamydia trachomatis; Trichomonas; microbicides; prevention
INTRODUCTION
The World Health Organization (WHO) estimates 328 million new cases of non-ulcerative 
sexually transmitted infections (STIs; Chlamydia, gonorrhoea, and trichomoniasis) occur 
every year around the world.1 Most of these incident infections occur in developing 
countries where STIs remain a significant public health problem and HIV is hyper-endemic. 
Those contracting STIs are at high risk for HIV acquisition because they may have recently 
been exposed to HIV,2 and the STI represents a biologic agent that increases the individual’s 
susceptibility to HIV. Trials have measured that persons with a non-ulcerative STI have a 3- 
to 4-fold increased risk of acquiring HIV.3–5 In HIV negative individuals, STIs increase 
susceptibility to HIV by recruiting HIV susceptible inflammatory cells to the genital tract 
and by disrupting mucosal barriers to infection.3
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With recognition that male-to-female sexual transmission is a major driver of the 21st 
century HIV-1 epidemic,6 a new focus in the past decade has been on the development of 
topical microbicide products for the prevention of HIV-1 that can be used with or without 
condoms and controlled by the receptive partner.7 Since vaginal microbicides have the 
ability to potentially interrupt both HIV as well as STIs, it is important to evaluate their 
potential efficacy in preventing HIV and STIs independently. In addition, if a microbicide 
demonstrates effectiveness in preventing HIV, it is useful to see if this impact is dependent 
or independent of its effects on STIs. Modelling studies predict that a microbicide active 
against curable STIs with a combined prevalence greater than 10% may substantially 
contribute to its effect on HIV prevention (by more than half), especially when the 
microbicide’s impact on preventing HIV is modest (i.e. ≤ 50% effectiveness).8 In the 
primary analysis of HIV Prevention Trials Network (HPTN) protocol 035, there was 
suggested benefit of 0.5% PRO 2000/5 Gel (P) (PRO 2000) in HIV prevention; however, a 
subsequent larger trial failed to confirm this. 910 In this study, we assessed the effectiveness 
of BufferGel and PRO 2000 in preventing non-ulcerative STI acquisition.
These candidate microbicides have promising preclinical data in support of their potential 
impact on non-ulcerative STIs. BufferGel was designed to exploit the natural defence 
against cervicovaginal infections found in acidic vaginal fluid1112 by maintaining an acidic 
pH in the vagina despite the presence of an alkaline ejaculate and was shown effective 
against Neisseria gonnorrhoeae (GC) and Chlamydia trachomatis (CT) in vitro and in 
some13–15 but not all animal models.1516 PRO 2000, a naphthalene sulfonate polymer, 
which has minimal effect on vaginal pH, was designed to block attachment and entry of 
STIs and HIV into host cells. Preclinical studies of PRO 2000 demonstrated in vitro and in 
vivo efficacy against GC and CT but not Trichomonas vaginalis (TV).131718
METHODS
Ethics approval
The trial (clinicaltrials.gov number NCT00074425) was approved and overseen by local 
ethics committees and institutional review boards at each study site.
Study Population
This study was conducted at 8 sites: Blantyre and Lilongwe, Malawi; Durban and Hlabisa, 
South Africa; Lusaka, Zambia; Chitungwiza and Harare, Zimbabwe; and Philadelphia, 
U.S.A. Women eligible for enrolment into study included HIV negative women 18 years or 
older in general good health, who had at least one episode of vaginal intercourse in the 3 
months preceding enrolment, and who were willing and able to provide informed consent 
and locator information. Women who were latex allergic, had used intravenous drugs in the 
preceding 12 months, had on average more than 2 sexual episodes per day in the 2 weeks 
preceding screening, had safety laboratory abnormalities, were recently pregnant or planned 
to become pregnant during the study, or had deep epithelial disruption on pelvic 
examination, were excluded.
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During screening, women were tested for cervical/vaginal infections, including GC and CT 
strand displacement assay (SDA) on urine samples and TV by microscopic evaluation of 
vaginal fluid (i.e., wet prep). Women diagnosed with active infection by these, or other, 
STIs at the time of screening were treated per WHO guidelines19 and were not enrolled 
unless treatment was completed and all symptoms had resolved within 30 days of obtaining 
informed consent for screening.
Women enrolling into the study were randomly assigned in equal proportions to one of four 
study arms [BufferGel vaginal gel, PRO 2000 vaginal gel, hydroxyethylcellulose (HEC) 
placebo vaginal gel, or no gel/condoms only]. Randomization was stratified by site, and the 
three gel groups were double-blinded while the no gel group was open label. All study gels 
were similar in appearance and were packaged in pre-filled, identical vaginal applicators. 
Women assigned to a gel arm were educated and instructed to insert one applicator of gel 
intravaginally ≤1 hour before each episode of vaginal intercourse, were given condoms and 
risk-reduction counselling, and were informed to contact study staff with questions or 
adverse events (AEs). Participants answered behavioural questionnaires during one-on-one 
interviews at enrolment and quarterly to assess number of partners, frequency and type of 
sex, use of condoms, adherence to study product, and any social harms resulting from study 
involvement. Medical evaluation included monthly visits and quarterly physical examination 
including pelvic examination and AE determination. All issues of reproductive health were 
addressed within the study facilities, including syndromic treatment for documented STIs. 
Study gels were held in the case of pregnancy or HIV seroconversion.
Laboratory Procedures
Quarterly laboratory procedures included saline wet mount of the vaginal smear, which was 
examined on site for the presence of motile TV. Specificity for TV by wet mount is 
approximately 100%, with a sensitivity of 51 to 66%, as compared to 70 to 85% by 
culture.20 Local referral laboratories for each site performed Bectin Dickinson Probe Tec ET 
GC and CT SDA from urine on individuals annually, at study exit, and as clinically 
indicated among participants with suspected cervicitis/vaginitis. Diagnostic test of cure 
following treatment was not performed. The BD Probe Tec ET urine assay has a specificity 
of more than 97% and a sensitivity of 80% as compared with culture methods.21 Additional 
laboratory procedures included evaluation for Candidiasis, bacterial vaginosis (BV), 
syphilis, type 2 herpes simplex virus, chancroid, and HIV. Clinical and laboratory staff at all 
sites underwent proficiency testing for on-site testing per protocol prior to study initiation 
and were subject to periodic review by DAIDS Clinical Site Monitoring Group for quality 
assurance.
Statistical Methods
The statistical rationale for the study design and sample size have been presented 
elsewhere;22 the primary analysis was intent-to-treat including all women with non-zero 
follow-up time. Incidence rates for GC, CT, and TV were calculated as the number of 
incident events (allowing for multiple events per participant) divided by the total person-
years at risk (PYAR). Results were calculated as number of events/100 PYAR. Two 
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controls, a placebo gel and a no gel comparator were utilized during this study to confirm 
that the near-neutral pH HEC placebo gel had no impact on risk of infection.23 The primary 
analysis of this study was a comparison of the effectiveness of BufferGel and PRO 2000 
versus placebo gel; however, the candidate microbicides were also compared to the no gel 
study group.
For each STI and study site, incidence rates were computed by study group as well as 
overall. The 95% confidence intervals (95% CI) around these estimates were calculated 
based upon methods for recurrent outcomes.24 Because women with STIs and other genital 
infections (and their partners) received treatments regarded to be effective at all sites, any 
infection detected during the follow-up periods was considered a new infection. Risk of STI 
acquisition by study arm was then determined by calculating hazard ratios (HRs) comparing 
the hazard of acquiring an STI while in the BufferGel or PRO 2000 groups to the hazard of 
acquiring an STI while in the placebo gel or no gel groups, using discrete time Andersen-
Gill proportional hazards model. Self-reported sexual risk behaviour data was collected at 
baseline and each quarterly follow-up visit. All data analysis was performed using SAS 
version 9.1.3 (SAS Institute, Cary, North Carolina, USA).
RESULTS
Of 5888 women screened for eligibility, 3101 (53%) were enrolled in the study. Of these, 
443 were from Blantyre, 600 from Lilongwe, 704 from Durban, 350 from Hlabisa, 320 from 
Lusaka, 260 from Chitungwiza, 224 from Harare, and 200 from Philadelphia. Fourteen 
women were excluded because of acute HIV infection at the time of enrolment (n=12) or 
duplicate enrolment (n=2). The remaining 3087 women were analysed by intention to treat 
for each study group as follows: 775 in BufferGel, 769 in PRO 2000, 771 in placebo gel, 
and 772 in no gel/condoms only.10 Overall, 2,889 (94%) women successfully completed the 
study, with similar rates across the four study groups (range: 93%–94%; p = 0.9). 
Individuals with no follow-up time (n=37) were excluded from analysis; those 3050 
contributing at least some time in follow-up, including the 2889 (94%) finishing study and 
161 (5%) lost to follow-up, were included in the primary intent-to-treat analysis and 
completed a median of 1.8 years follow-up during study from February 2005 to September 
2008.
Baseline characteristics did not significantly differ between the four treatment arms 
including age, education, marriage, cohabitation, sexual behaviour, and baseline prevalence 
of non-ulcerative STIs (GC, CT, TV) identified at each site during screening (Table 1) as 
well as pelvic exam findings and safety laboratory measures (data not shown). Certain 
characteristics varied significantly by site, such as condom use and report of ever having had 
anal sex. At enrolment, the proportion of women reporting condom use during their last 
vaginal sex act ranged from 52%–87% among study sites but was similar within the four 
treatment groups (range: 67%–69%). 46% of participants at the Philadelphia site reported a 
history of engaging in anal sex compared to only 0.3% – 4.1% of women within the African 
sites.
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Gel groups and the no gel/condoms only group were counselled identically in a 
comprehensive fashion and encouraged to use condoms at each sexual encounter. 600,672 
male condoms were distributed among study participants. Reported condom use at last 
vaginal sex ranged from 73% to 76% during the first 12 months. Self-reported condom use 
during the last sexual act was similar in the three gel arms, but higher in the no gel arm 
(71.7% vs 80.7%, p<0.0001). Reported gel use at last sex was 81% (range: 75–94% across 
the sites) and was not significantly different between the three gel groups (range 80.6%–
81.5%). Overall, women reported gel use in conjunction with condoms during study follow-
up in 61.3% of sex acts. Gel products were used in 69.1% of last sex acts in which a condom 
was not used, among those in the three gel arms. Gel acceptability was high, and 99% of 
women stated at study exit that they would use a microbicide gel if it were found effective. 
The safety profiles of both BufferGel and PRO 2000 were excellent.10
Incidence of STIs varied substantially by location (Table 2). Hlabisa, the site with the 
highest incidence of HIV, had the highest incidence rates of GC, CT and TV. Among study 
clinics, incidence of GC trended similarly to incident HIV, whereas CT and TV did not. 
Overall, 82 cases of GC were diagnosed in 76 women over 5115 person-years (incidence 
rate: 1.6 cases/100 PYAR; 95% CI: 1.2–2.0). Incident GC rates were lowest at the U.S. site 
(0.2 cases/100 PYAR; 95% CI: −0.3–0.8) and highest at the Durban and Hlabisa sites (2.0 
cases/100 PYAR; 95% CI: 1.2–2.9 and 3.0 cases/100 PYAR; 95% CI: 1.4–4.6, 
respectively). Participants in the PRO 2000 arm had the highest incidence rate of GC (2.2 
cases/100 PYAR; 95% CI: 1.3–3.0) but it was not statistically different from the other 
treatment groups, overall or by site, as indicated by overlapping 95% confidence intervals 
with incidence rates among the BufferGel, placebo or no gel arms (Figure 1A).
Cases of CT occurred 198 times in 180 women during 5115 person-years follow-up for an 
overall incidence of 3.9 cases/100 PYAR (95% CI: 3.3–4.4) at all sites. Incident CT was 
more common in Hlabisa (10.3 cases/100 PYAR; 95% CI: 7.6–13.0) and Durban (6.4 
cases/100 PYAR; 95% CI: 4.9–7.9) as compared to the remaining sites (Table 2). Incidence 
of CT by treatment group was not different (Figure 1B).
TV was diagnosed 792 times in 521 women during 5177 person-years of follow-up for an 
overall event rate of 15.3 cases per 100 PYAR (95% CI: 13.9–16.7) for all sites. Rates were 
highest in Hlabisa (33.6 cases/100 PYAR; 95% CI: 28.0–39.1) and Philadelphia (25.7 
cases/100 PYAR; 95% CI: 18.9–32.5). Incidence at the remaining sites were statistically 
significantly lower than in Hlabisa. All remaining sites’ rates but Lilongwe’s were lower 
compared to the Philadelphia site’s rate (Table 2). Estimates of TV were not statistically 
different among treatment groups (Figure 1C).
To examine the impact of study products on incidence of non-ulcerative STIs, HRs for STI 
acquisition were calculated for BufferGel and PRO 2000 as compared to either placebo gel 
or no gel controls (Table 3). HRs for acquiring GC, CT, or TV in the BufferGel group, as 
compared to the placebo gel group, were 0.99, 1.00 and 0.95, with 95% CIs crossing 1.0 in 
all cases, indicating no effect on STIs by BufferGel. HRs for acquisition of STIs when 
BufferGel was compared to the no gel control group were also not statistically significant, 
with 95% CI of HRs crossing 1.0 for each group. Among those in the PRO 2000 arm, there 
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was a tendency toward higher acquisition of GC as compared to the placebo gel group (HR 
1.66; 95% CI: 0.90–3.06) and the no gel group (HR 1.45; 95% CI: 0.78–2.70) but neither 
finding was statistically significant. The HRs for acquisition of CT and TV among those in 
the PRO 2000 group as compared to the placebo gel group were 1.16 (95% CI 0.76, 1.79) 
and 1.18 (95% CI 0.90, 1.53), respectively, demonstrating no efficacy of PRO 2000 against 
these organisms. Similarly, no statistical differences were seen when comparing the PRO 
2000 group with the no gel group, with all 95% CIs crossing 1.0. Finally, the HRs for 
incident GC, CT and TV for individuals in the placebo gel group were compared to those in 
the no gel group. No statistically significant differences were found among these 
comparisons.
DISCUSSION
Neither BufferGel nor PRO 2000 demonstrated a statistically significant protective effect 
against any of the three non-ulcerative STIs when compared to placebo gel or no gel 
controls in this study. While HPTN 035 primary findings suggested benefit toward 
decreased risk of HIV acquisition among women randomized to PRO 2000 (no effect among 
those using BufferGel), this result was subsequently not confirmed in a larger trial.910 In this 
study, we went further to suggest that these two microbicides were also not effective in 
blocking male-to-female sexual transmission of bacterial and protozoan pathogens.
Strengths of this analysis include that HPTN 035 was a multinational, randomized, placebo-
controlled, clinical trial evaluating candidate microbicides BufferGel and PRO 2000 for the 
capacity to reduce sexually transmitted infections. STI prevalence in participants at 
screening (0.7% GC, 3.5% CT, 7.3% TV) was similar to that anticipated, based on 
preparatory study HPTN 055 in Hlabisa and Durban, South Africa, and Lusaka, Zambia,25 
and during HPTN 035, these STIs occurred at rates of 1.6, 3.9, and 15.3 per 100-person 
years (GC, CT, and TV, respectively). Reported uptake of gel products was adequate (81% 
in all groups by self-report), and no risk compensation was identified as a result of gel usage 
as compared to the no gel group. Evidence for this includes that while the three gel arms 
were somewhat less likely to report using condoms than the no gel arm, there was no evident 
effect on non-ulcerative STI acquisition, as indicated by incidence of STIs among those in 
the placebo gel arm as compared to no gel control.26
The study did have limitations. Firstly, non-culture methods were used for assessment of 
outcomes. While we believe sensitivity of detection was adequate for determination of 
incident infections, the measurement of STIs may have been fewer, as compared to culture 
methods, or other modalities (e.g., direct swab), resulting in an underestimate of the number 
of infections and potentially reduce statistical power to observe a treatment effect. 
Additionally, it is possible that some of the studied STIs may have been treated 
unintentionally by receipt of antimicrobials for non-reproductive indications during the 
intervening time between assessments. We do believe however that this was a rare event, as 
the majority of all care was received within study clinics. Throughout, the overall reported 
use of condoms at last vaginal sex was 74% (range 51%–77%), but it is very likely that self-
reported condom use was an overestimate of actual use, and probable that the residual 
unprotected sexual acts remained sufficient to account for the STI transmissions. Low 
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uptake of condoms in some of these communities and reasons for this have been previously 
identified highlighting the limitation of using condoms for STI and HIV prevention in 
women in many African communities25 since women may not be able to negotiate their use 
with male partners.27 Reported condom use was higher in the no gel group compared to the 
gel arms (81% vs. 72%), but this modest difference in self-reported condom use did not 
correlate with a decreased incidence of STIs in the no gel group.
The discordance between the results of this clinical trial and preclinical evaluations could be 
interpreted in two ways. First, these data could suggest that in vitro assays and animal model 
studies may overestimate the effectiveness of these agents when used vaginally within the 
context of sexual exposure. An alternative hypothesis is that the products were somewhat 
effective, but that actual adherence to product was lower than that reported by study 
participants, which minimized the power to detect a difference in the rates of incident STIs. 
Other prevention trials among similar populations, which have evaluated adherence by drug 
levels, suggest more modest levels of adherence despite high measures of adherence by self-
report.28 HPTN 035 measured adherence only through self report through one-on-one 
interviews, which is a methodology with greater susceptibility to social desirability bias than 
measurement by drug levels, or applicator biomarkers, such as used in other studies of 
microbicides,29 or other modalities such as audio computer assisted self interview 
(ACASI).30
Though GC was less common at the U.S. site, Philadelphia had CT and TV rates similar to 
the women enrolled in the African sites. Among African sites, those in South Africa, 
especially, had high rates of non-ulcerative STIs. The tendency toward higher rates of non-
ulcerative STIs among women enrolled from South Africa sites compared to those seen in 
other African countries paralleled the higher risk of HIV observed at sites in South Africa in 
this study. Additionally, antibiotic resistance in GC, which was increasing in prevalence 
during the time of study,31 may have contributed to differences between centres, although 
not to the randomized comparison in treatment groups.
Given the high prevalence, cost, and morbidity associated with non-ulcerative STIs and the 
lack of effective prevention modalities, an effective microbicide would become an important 
tool to reduce the burden of STIs. Though BufferGel and PRO 2000 microbicide gels were 
accepted by users and shown to be safe,10 neither was found effective at preventing non-
ulcerative STIs. While recent trials have focused on pre-exposure prophylaxis using 
antiretroviral therapy to prevent HIV transmission, it remains important to keep the research 
pipeline flowing for the development and testing of specific and broadly acting compounds 
that will be effective against these important pathogens, because of their high morbidity, as 
well as their potential impact on combination HIV prevention.
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• HPTN 035, a randomized controlled trial of 3099 women, identified high rates 
of non-ulcerative STIs among women in eight international sites, despite 
intensive risk-reduction counselling.
• The impact of condom use in the three gel arms, versus the no gel control arm, 
had no evident effect on non-ulcerative STI acquisition.
• Vaginal microbicides BufferGel and 0.5% PRO 2000 showed no significant 
effect for the prevention of Neisseria gonorrhoeae, Chlamydia trachomatis, or 
Trichomonas vaginalis.
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Figure 1. Incidence rates of non-ulcerative STIs by treatment group and location
Incidence rates are calculated as the number of new infections per 100 person-years at risk 
(PYAR) for incident Gonorrhoea (A), Chlamydia (B), and Trichomoniasis (C). Incidence 
rates are indicated by treatment group including: all groups combined (■), BufferGel (●), 
PRO 2000 (○), Placebo Gel (✖), and No Gel/Condoms Only (−), and 95% confidence 
intervals are shown as vertical lines. For each STI, incidence rates at all sites combined are 
presented first, followed by rates of infection at each site.
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